前列地尔联合厄贝沙坦治疗糖尿病肾病蛋白尿的临床观察  

Clinical Observation of Alprostadil Combined with Irbesartan in the Treatment of Proteinuria in Diabetic Nephropathy

作　　者：于涛 YU Tao(Department of Internal Medicine,the Second Hospital of Donggang City,Donggang 118313,China)

机构地区：[1]东港市第二医院内一科,辽宁东港118313

出　　处：《中国医药指南》2022年第21期94-97,共4页Guide of China Medicine

摘　　要：目的评价糖尿病肾病蛋白尿行联合治疗(前列地尔联合厄贝沙坦)的可行性与临床效果,为糖尿病肾病临床治疗提供参考。方法选择我院2018年5月至2019年5月收治治疗的糖尿病肾病蛋白尿患者,总计80例。采取随机法数字表法,进行80例受试人群分组治疗。常规降糖等治疗的基础上,参照组(n=40)糖尿病肾病蛋白尿患者行前列地尔治疗,观察组(n=40)糖尿病肾病蛋白尿患者行前列地尔+厄贝沙坦治疗。对比两组糖尿病肾病蛋白尿患者的具体治疗情况,包括治疗效果、安全性、血肌酐、三酰甘油、总胆固醇水平以及24 h尿微量白蛋白排泄量、尿蛋白含量变化情况。结果治疗效果方面,与参照组患者比较,观察组患者治疗后总有效率(95.00%)更高,P<0.05;治疗后血肌酐、三酰甘油、总胆固醇水平方面,与参照组患者比较,观察组患者治疗后水平低,P<0.05;治疗后24 h尿微量白蛋白排泄量、尿蛋白含量方面,与参照组患者比较,观察组患者治疗后水平低,P<0.05;另外,两组糖尿病肾病蛋白尿患者组间干咳、头晕、血管炎等不良反应情况(12.50%vs.10.00%)比较,P>0.05差异无显著性。结论对比单一用药治疗,糖尿病肾病蛋白尿行前列地尔联合厄贝沙坦治疗可以进一步改善患者的肾功能、减少蛋白尿,治疗具有安全性、有效性价值。Objective To evaluate the feasibility and clinical effect of combined treatment of proteinuria in diabetic nephropathy(alprostadil combined with irbesartan),and to provide references for clinical treatment of diabetic nephropathy.Methods A total of 80 patients with diabetic nephropathy and proteinuria admitted to our hospital from May 2018 to May 2019 were selected.A randomized number table method was adopted to treat 80 subjects in groups.On the basis of conventional hypoglycemic treatment,the reference group(n=40)patients with diabetic nephropathy and proteinuria were treated with alprostadil,and the observation group(n=40)patients with diabetic nephropathy and proteinuria were treated with alprostadil and irbesartan.The specific treatment conditions of the two groups of diabetic nephropathy patients with proteinuria were compared,including the treatment effect,safety,blood creatinine,triacylglycerol,total cholesterol levels,and changes in 24 h urine microalbumin excretion and urine protein content.Results In terms of treatment effect,compared with the reference group,the observation group had a higher total effective rate(95.00%)after treatment,P<0.05;in terms of serum creatinine,triacylglycerol,and total cholesterol levels after treatment,compared with the reference group,the observation group had a low level after treatment,P<0.05;24 h after treatment,urine microalbumin excretion and urine protein content,compared with the reference group,the observation group had a low level after treatment,P<0.05;in addition,two groups comparison of adverse reactions such as dry cough,dizziness,and vasculitis(12.50%vs.10.00%)among the groups of patients with diabetic nephropathy and proteinuria showed no significant difference in P>0.05.Conclusion Compared with single-drug treatment,alprostadil combined with irbesartan treatment for diabetic nephropathy proteinuria can further improve the patient’s renal function and reduce proteinuria.The treatment has safety and effectiveness.

关 键 词：前列地尔 厄贝沙坦 糖尿病肾病蛋白尿 治疗效果 安全性 肾功能 

分 类 号：R587.2[医药卫生—内分泌]